Results 311 to 320 of about 1,440,912 (355)

Corporate governance and the early disclosure of systematic risk

Canadian Journal of Administrative Sciences / Revue Canadienne des Sciences de l'Administration, EarlyView.
Abstract Motivated by the need to understand firm characteristics associated with the disclosure of unexpected and unusual systematic risks, caused by events over which managers have little control, we examine the association between corporate governance and the early disclosure of such risks.
Abiodun S. Isiaka, Chima Mbagwu
wiley   +1 more source

A multivariate Poisson model based on a triangular comonotonic shock construction

Canadian Journal of Statistics, EarlyView.
Abstract Multi‐dimensional data frequently occur in many different fields, including risk management, insurance, biology, environmental sciences, and many more. In analyzing multivariate data, it is imperative that the underlying modelling assumptions adequately reflect both the marginal behaviour and the associations between components.
Orla A. Murphy, Juliana Schulz
wiley   +1 more source

Use of Real‐World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug–Drug Interaction Risk in Target Patient Populations

Clinical Pharmacology &Therapeutics, EarlyView.
A common issue in clinical drug development involves drug–drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population.
Alice S. Tang, Logan Brooks, Denise M. Boudreau, Pascal Chanu, Amita Joshi, Bianca Vora, Rui Zhu   +6 more
wiley   +1 more source

A quantitative evaluation study of China's Long-Term Care insurance policies based on the PMC index model: A case study of 16 pilot policy texts. [PDF]

PLoS One
Wang Y, Wang W, Zhang Y, Zeng Y.
europepmc   +1 more source

Supplementing Single‐Arm Trials with External Control Arms—Evaluation of German Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
As single‐arm trials (SATs) are increasingly used in pharmaceutical research, the validity of such study designs needs to be critically assessed. We characterize the feasibility of supplementing SATs with real‐world data (RWD)‐derived external control arms by determining the proportion of SATs on breast cancer and amyotrophic lateral sclerosis (ALS ...
Martin Russek, Jonas Peltner, Britta Haenisch   +2 more
wiley   +1 more source

Why do rural residents in China withdraw from the health insurance system? -A qualitative study based on Y County in S Province, China. [PDF]

BMC Public Health
Zuo Y, Yang G, Cheng H, Zhang L.
europepmc   +1 more source

Politically Sustainable Social Insurance [PDF]

Christopher Sleet, Sevin Yeltekin
core  

Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test

Clinical Pharmacology &Therapeutics, EarlyView.
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions.
James M. Stevenson, D. Max Smith, Sony Tuteja, Jai N. Patel, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +4 more
wiley   +1 more source

A computational grounded theory based analysis of research on China's old-age social welfare system. [PDF]

Front Public Health
Agudamu, Li Y, Mi N, Pan X.
europepmc   +1 more source